Skip to main navigation Skip to search Skip to main content

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

  • Michael R. Harrison
  • , Noah M. Hahn
  • , Roberto Pili
  • , William K. Oh
  • , Hans Hammers
  • , Christopher Sweeney
  • , Kyung Mann Kim
  • , Scott Perlman
  • , Jamie Arnott
  • , Carolyn Sidor
  • , George Wilding
  • , Glenn Liu

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry